glp 1 and bulimia 504: Adult Eating Disorders in the GLP-1 Era Nutritional priorities to support GLP-1

Description

Issue 42 of The Altascientist explores GLP-1 receptor agonist drug development, covering preclinical models, bioanalytical assays, clinical study design, and manufacturing

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical organizations to speak out about safety concerns.In December, the FDA released a statement to health care professionals and patients warning against the use of compounded and counterfeit versions of diabetes and obesity drugs, including semaglutide (Ozempic/Wegovy, Novo

Progestins are a safe and highly effective ...

For more info, please read our ad policy, content principles and vetting policy.

Semaglutide can support modest weight loss goals like 15 pounds, but outcomes depend on starting dose, treatment duration, lifestyle factors, and individual genetic predispositions in GLP-1 receptor pathways